Resources Repository
-
OrganizationWeb Portal 2024Agency for Healthcare Research and Quality (AHRQ)
The Agency for Healthcare Research and Quality (AHRQ) is the nation's lead federal agency for …
The Agency for Healthcare Research and Quality (AHRQ) is the nation's lead federal agency for research on health care quality, costs, outcomes and patient safety. AHRQ is the health services research arm of the U.S. Department of Health and Human Services (HHS), complementing the biomedical research mission of its sister agency, the National Institutes of Health. The agency is home to research centers that specialize in major areas of health care research, including: clinical practice…
North America | Policy/Regulation | Child/Nutrition | Costing Methods | Health Outcomes | Test Performance | Decision Analysis | Cost-Effectiveness Analysis | Technology Assessment | Infectious Diseases | Maternal/Reproductive Health | Chronic Disease/Risk | Mental Health | Injuries/Accidents | Social Determinants | Health Systems | Economics/Finance | Government/Law | Health/Medicine | Science/Technology -
Lesson/ModuleWeb Portal, Teaching Resource 2016Scientific Evidence of Factual Causation
This module examines three scientific areas that provide evidence bearing on causation in the “toxic …
This module examines three scientific areas that provide evidence bearing on causation in the “toxic tort” or environmental disease context: epidemiology, toxicology, and genetics. These scientific disciplines are used in civil lawsuits and in regulatory proceedings in which causation or risk is an issue. The module is appropriate for non-scientist law students as well as others interested in learning the science of toxic tort causation, including practicing attorneys, judges, and public policy and public health…
North America | Policy/Regulation | Child/Nutrition | Evidence Synthesis | Risk Analysis | Chronic Disease/Risk | Environmental Health | Climate/Environment | Food/Agriculture | Government/Law | Health/Medicine | Science/Technology | Global | College | Graduate | Doctoral | Professional | Critical Thinking/Analysis | Quantitative Literacy -
ArticlePublication 2015Three Interventions That Reduce Childhood Obesity
Policy makers seeking to reduce childhood obesity must prioritize investment in treatment and primary prevention. …
Policy makers seeking to reduce childhood obesity must prioritize investment in treatment and primary prevention. The authors estimated the cost-effectiveness of seven interventions high on the obesity policy agenda: (1) a sugar-sweetened beverage excise tax, (2) elimination of the tax subsidy for advertising unhealthy food to children, (3) restaurant menu calorie labeling, (4) nutrition standards for school meals, (5) nutrition standards for all other food and beverages sold in schools, (6) improved early care and…
North America | Policy/Regulation | Child/Nutrition | Costing Methods | Cost-Effectiveness Analysis | Health Systems | Clinical Care | Economics/Finance | Health/Medicine -
ReviewPublication 2015Medicare's Use of CEA for Prevention (But Not Treatment)
Medicare currently pays for 23 preventive services in its benefits package, the majority of which …
Medicare currently pays for 23 preventive services in its benefits package, the majority of which were added since 2005. In the past decade, the program has transformed from one essentially administering treatment claims, to one increasingly focused on health promotion and maintenance. What is largely unappreciated is the role cost-effectiveness analysis has played in the coverage of preventive services. This study reviews the role of cost-effectiveness analysis in Medicare coverage of preventive services and contrast it…
North America | Policy/Regulation | Child/Nutrition | Priority Setting/Ethics | Cost-Effectiveness Analysis | Technology Assessment | Infectious Diseases | Chronic Disease/Risk | Health Systems | Economics/Finance | Government/Law | Health/Medicine -
ArticlePublication 2021Racial and Ethnic Inequities in the Early Distribution of U.S. COVID-19 Testing Sites and Mortality
In 2020, U.S. COVID-19 testing sites were pivotal not just for diagnosis but also to …
In 2020, U.S. COVID-19 testing sites were pivotal not just for diagnosis but also to provide data that would contribute to understanding transmission. This research explored how these sites were distributed in relation to racial and ethnic demographics and its connection to observed disparities in COVID-19 outcomes. Data from mid-April to late May 2020 revealed that testing sites were not equally distributed among racial groups. Specifically, there was an overrepresentation of testing sites in areas…
North America | Policy/Regulation | Health Outcomes | Test Performance | Infectious Diseases | Social Determinants | Culture/Society | Health/Medicine | Science/Technology -
ArticlePublication 2023Benefits and Costs of COVID-19 Vaccine Mandates
Written mid-pandemic, this article evaluates the direct costs and health benefits of requiring COVID-19 vaccinations …
Written mid-pandemic, this article evaluates the direct costs and health benefits of requiring COVID-19 vaccinations for U.S. federal employees and healthcare and private sector workers. These mandates were controversial and some were halted by litigation. If they had been implemented as intended, the net benefits would depend on the course of the pandemic. If a more transmissible variant (such as Omicron) emerges, the net benefits may be large. If the pandemic instead fades, the benefits…
North America | Policy/Regulation | Mathematical Models | State-Transition | Benefit-Cost Analysis | Infectious Diseases | Business/Industry | Economics/Finance | Government/Law | Health/Medicine -
EditorialPublication 2019Quality Transparency in Health Care
The immediate promise of using public reporting to increase quality transparency is that it will …
The immediate promise of using public reporting to increase quality transparency is that it will enable consumers to choose the providers best suited to their needs and thereby lead to improved patient outcomes and welfare. Unfortunately, however, early empirical findings failed to detect such anticipated benefits from public reporting. For example, studies have indicated that the launch of the Hospital Compare website and other efforts aimed at increasing quality transparency have not resulted in improved…
North America | Policy/Regulation | Health/Medicine -
ArticlePublication 2022COVID-19 Response: The Need for Economic Evaluation
COVID-19-related policies are fraught with trade-offs. Many of these trade-offs involve dimensions that can be …
COVID-19-related policies are fraught with trade-offs. Many of these trade-offs involve dimensions that can be quantitatively weighed using economic evaluation, such as those between health and cost outcomes. Other types of dimensions, such as those involving equity or autonomy, can be harder to quantify but should be considered in a comprehensive health policy decision-making context nonetheless. The authors of this New England Journal of Medicine Perspectives article outline how methods of economic evaluation and decision…
North America | Policy/Regulation | Priority Setting/Ethics | Benefit-Cost Analysis | Cost-Effectiveness Analysis | Infectious Diseases | Economics/Finance | Health/Medicine | Global -
ArticlePublication 2022Emerging Therapies for COVID-19: The Value of Information From More Clinical Trials
The COVID-19 pandemic necessitated time-sensitive policy and implementation decisions regarding new therapies in the face …
The COVID-19 pandemic necessitated time-sensitive policy and implementation decisions regarding new therapies in the face of uncertainty. This study aimed to quantify consequences of approving therapies or pursuing further research. The authors used a cohort state-transition model for hospitalized patients with COVID-19 to estimate quality-adjusted life-years (QALYs) and costs associated with multiple drug regimens and usual care. For each they assessed immediate approval, use only in research, emergency use authorization or reject. They conducted cost-effectiveness…
North America | Policy/Regulation | Value of Information | State-Transition | Benefit-Cost Analysis | Infectious Diseases | Economics/Finance | Europe